- Bronchitis is one of the most common respiratory diseases observed in developed as well as developing countries.
- A patient suffering with acute bronchitis takes 1 to 2 weeks to recover while in case of chronic bronchitis it takes 2 to 3 months.
- Bacterial infections in developed & developing countries are affecting the market greatly..
Bronchitis is one of the most common respiratory diseases observed in developed as well as developing countries. Chronic bronchitis is life-threatening most of the times and the Centers for Disease Control and Prevention recorded that 8.6 million people were diagnosed with chronic bronchitis in year 2016 in the U.S with 0.2% of mortality.
However, as the U.S is more developed country, mortality rate is low. But in developing and under developed countries the mortality rate is in range of 3% – 4%. Bronchitis is triggered due to several factors common cold & flu, and other bacterial infections which leads to airway obstruction due to inflammation of bronchial walls.
A patient suffering with acute bronchitis takes 1 to 2 weeks to recover while in case of chronic bronchitis it takes 2 to 3 months. However, overall drug pipeline of bronchitis treatment is strong as there are several combination therapies present that provide target-specific performance.
The global Bronchitis Treatment market was valued at $3,345.8 Mn in 2017, and is expected to reach $4,606.3 Mn by 2026, expanding at a CAGR of 4.9% from 2018 to 2026.
In 2017, bronchodilators was identified as the largest growing segment in bronchitis treatment market due to key factors such as rising prevalence related to bronchitis, and increasing awareness campaigns related to chronic bronchitis, & other bacterial infections in developed & developing countries.
The awareness activities carried out in developing and under developed countries have helped to increase the diagnosis rate in last couple of years. Bronchodilators are always the first-line drugs for treatment of bronchitis as the clearing airway obstruction is the most important thing in chronic bronchitis to ease the breathing of patient.
North America was observed as the largest bronchitis treatment market due to rising prevalence coupled with high prevalence of bronchitis, and increasing trend of smoking in young generation have assisted the slight rise in the prevalence rate, developed & accessible diagnostic technologies. According to Pharmaprix, about 1 in 20 people suffers with chronic bronchitis in North America. In addition to this, North America bronchitis market is also growing due to ongoing development in research of bronchitis treatment drug pipeline.
- Buy Research Report: Global Osseointegration Implants Market Size Valued at US$ 5,672.3 Million in 2017
- Buy Research Report: Global Oncology Drugs Market Estimated to Reached US$ 77.3 Billion in 2018
- I Will Remove Background of Your Picture (for Amazon, Ebay Ads Listing)
- Buy Research Report: Skin Care Products Market Analysis
- Buy Research Report: Antimicrobial Susceptibility Testing Market to Witness a CAGR of 6.2% Over the Forecast Period (2018 – 2026)
Market Competition Assessment
The bronchitis treatment market is growing steadily and major companies operating in this market are developing treatments that are safe and target-specific. The major companies available in the global market are AstraZeneca Plc, DBV Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., and Mucosis BV among others.
Key Market Movements
Rising awareness and prevalence related to bronchitis treatment & diagnosis is expected to assist market growth. Incessant growth in research & development of bronchitis treatment will assist the growth in demand for safe & efficient treatment options. Mounting diagnosis rates related to developing countries will increase demand for the bronchitis treatment market. A strong drug pipeline is expected to increase the CAGR of the overall market in the near future.
List of Companies Covered: Advanced Inhalation Therapies (AIT) Ltd., AstraZeneca Plc, DBV Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., Kyorin Pharmaceutical Co Ltd., Merck & Co., Mucosis BV, Orbis Biosciences, Inc., Therabron Therapeutics, Inc., GlaxoSmithKline plc, Chong Kun Dang Pharmaceutical, ONY Biotech Inc., Genentech, Inc., Daewon Pharm Co. Ltd.
By Type of Drug Class (Antitussives/expectorants, Bronchodilators .Beta-adrenergic agonist .Systemic corticosteroids, Inhaled corticosteroids, Phosphodiesterase-4 inhibitors, Analgesics, and Antibiotics).
North America (the U.S., Rest of North America), Europe (U.K., Germany, France, Rest of Europe), Asia Pacific (China, Japan, India, Rest of Asia Pacific), Rest of the World (the Middle East & Africa, Latin America)